Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology
暂无分享,去创建一个
G. Filippatos | L. Lund | E. Arbustini | A. Oto | M. Metra | S. Anker | A. Coats | J. Čelutkienė | P. Seferovic | F. Ruschitzka | G. Rosano | M. Piepoli | S. Felix | C. Rapezzi | T. Jaarsma | C. Tschöpe | J. Backs | G. Limongelli | C. Mueller | J. Bauersachs | A. Ristic | D. Miličić | M. Ašanin | M. Volterrani | D. Farmakis | R. A. Boer | A. Lyon | W. Mullens | T. Gal | A. Caforio | A. Linhart | L. Hill | M. Arad | E. Gialafos | R. Maksimovic | M. Noutsias | V. Kanjuh | O. Chioncel | J. Seferovic | H. Seggewiss | S. Pavlovic | M. Polovina | I. Milinković | Ö. Oto | B. Moura | G. Krljanac | Y. Lopatin | Ivan Milinković
[1] S. Solomon,et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study , 2019, Circulation.
[2] K. Soejima,et al. Management of Arrhythmias Associated with Cardiac Sarcoidosis , 2019, Korean circulation journal.
[3] D. Pennell,et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.
[4] W. Rottbauer,et al. Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure—A Single Center Experience , 2018, Biomolecules.
[5] John M. Shelton,et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy , 2018, Science.
[6] W. Helbing,et al. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase. , 2018, International journal of cardiology.
[7] M. Mack,et al. Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.
[8] A. Lyon,et al. Activity and outcomes of a cardio‐oncology service in the United Kingdom—a five‐year experience , 2018, European journal of heart failure.
[9] D. Maucort-Boulch,et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.
[10] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[11] Susanna Price,et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.
[12] M. Maurer,et al. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. , 2018, Journal of cardiac failure.
[13] P. Elliott,et al. Anderson-Fabry disease in heart failure , 2018, Biophysical Reviews.
[14] D. Pennell,et al. Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy , 2018, European journal of heart failure.
[15] L. Tavazzi,et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies , 2018, European heart journal.
[16] A. Cohen-Solal,et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge , 2018, European journal of heart failure.
[17] G. Filippatos,et al. Anthracycline‐induced cardiomyopathy: secrets and lies , 2018, European journal of heart failure.
[18] B. Maron,et al. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. , 2018, JACC. Heart failure.
[19] N. Pereira,et al. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. , 2018, Journal of the American College of Cardiology.
[20] C. Wanner,et al. Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy , 2018, European heart journal.
[21] D. Freimark,et al. De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. , 2018, International journal of cardiology.
[22] G. Helbig. Imatinib for the treatment of hypereosinophilic syndromes , 2018, Expert review of clinical immunology.
[23] Y. Naka,et al. Outcome of heart transplantation after bridge-to-transplant strategy using various mechanical circulatory support devices. , 2017, Interactive cardiovascular and thoracic surgery.
[24] D. Patsouras,et al. Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment—A Systematic Review , 2017, Radiology research and practice.
[25] A. Brandes,et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure , 2017, Circulation.
[26] L. Zentilin,et al. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption , 2017, Circulation research.
[27] M. Leon,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.
[28] M. Gertz,et al. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.
[29] U. Eriksson,et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease , 2017, European heart journal.
[30] M. Claeys,et al. Evolution of Functional Mitral Regurgitation and Prognosis in Medically Managed Heart Failure Patients With Reduced Ejection Fraction. , 2017, JACC. Heart failure.
[31] A. Gasbarrini,et al. Alcoholic cardiomyopathy: What is known and what is not known. , 2017, European journal of internal medicine.
[32] H. Mølgaard,et al. Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis , 2017, European journal of heart failure.
[33] K. Sliwa,et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study , 2017, European heart journal.
[34] B. Maron,et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. , 2017, Annals of cardiothoracic surgery.
[35] P. Elliott,et al. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis , 2017, Circulation.
[36] P. Elliott,et al. Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement , 2017, Journal of cardiovascular medicine.
[37] J. Politei,et al. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies , 2017, PloS one.
[38] C. Rochitte,et al. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial , 2017, JAMA cardiology.
[39] M. Ohlow,et al. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry. , 2017, Journal of cardiology.
[40] D. Lockhart,et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study , 2016, Journal of Medical Genetics.
[41] U. Landmesser,et al. Restrictive cardiomyopathy , 2017, Wiener klinische Wochenschrift.
[42] C. Yancy,et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. , 2016, Circulation.
[43] B. Gersh,et al. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. , 2016, Journal of the American College of Cardiology.
[44] P. Elliott,et al. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy , 2016, Heart.
[45] L. Lund,et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[46] G. Lip,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.
[47] R. Falk,et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.
[48] K. Sliwa,et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy , 2016, European journal of heart failure.
[49] J. Seidman,et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.
[50] C. Rapezzi,et al. Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts , 2016, Circulation. Heart failure.
[51] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[52] L. Lund,et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[53] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[54] D. DeMets,et al. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. , 2016, JACC. Heart failure.
[55] D. Phelan,et al. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. , 2016, Journal of the American College of Cardiology.
[56] S. Cook,et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[57] B. Pieske,et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy , 2016, Clinical Research in Cardiology.
[58] S. Heymans,et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.
[59] É. Marijon,et al. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives , 2016, Circulation.
[60] B. Bijnens,et al. High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease , 2016, Journal of the American Heart Association.
[61] E. Arbustini,et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy , 2016, Clinical Research in Cardiology.
[62] L. Axel,et al. The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. , 2016, Journal of the American College of Cardiology.
[63] M. Link,et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[64] L. Lund,et al. Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012 , 2016, European journal of heart failure.
[65] Andrea Mazzanti,et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.
[66] Mark D. Huffman,et al. Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.
[67] J. Seidman,et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.
[68] L. Lund,et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[69] M. Hannan,et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[70] A. Ha,et al. Cardiac Sarcoidosis. , 2016, Journal of the American College of Cardiology.
[71] M. Benson,et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. , 2015, Journal of the American College of Cardiology.
[72] Deepak L. Bhatt,et al. Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. , 2015, JACC. Heart failure.
[73] F. Girolami,et al. Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy , 2015, Circulation. Heart failure.
[74] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[75] K. Roszkowski-Śliż,et al. Cardiac Sarcoidosis: Is it More Common in Men? , 2015, Lung.
[76] Andrew J. Sauer,et al. "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. , 2015, JACC. Heart failure.
[77] Y. Gerber,et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[78] M. Link,et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.
[79] J. Airaksinen,et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.
[80] P. Elliott,et al. Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease , 2015, Heart.
[81] S. Raman,et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial , 2015, The Lancet Neurology.
[82] Tan Ru San,et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.
[83] S. Piechnik,et al. T1 mapping and survival in systemic light-chain amyloidosis , 2014, European heart journal.
[84] D. Judge,et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs , 2015, Heart Failure Reviews.
[85] F. Rutten,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[86] C. Tschöpe,et al. Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome , 2014, European journal of heart failure.
[87] W. Roberts,et al. Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant , 2014, Circulation. Heart failure.
[88] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[89] L. Mestroni,et al. Danon Disease: Clinical Features, Evaluation, and Management , 2014, Circulation. Heart failure.
[90] E. Cook,et al. Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.
[91] J. Healey,et al. Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middle‐Aged Adults , 2014, Journal of cardiovascular electrophysiology.
[92] R. Hauer,et al. Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.
[93] Amit R. Patel,et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.
[94] K. Sliwa,et al. Pathophysiology and epidemiology of peripartum cardiomyopathy , 2014, Nature Reviews Cardiology.
[95] J. Banner,et al. The presence of enterovirus, adenovirus, and parvovirus B19 in myocardial tissue samples from autopsies: an evaluation of their frequencies in deceased individuals with myocarditis and in non-inflamed control hearts , 2014, Forensic Science, Medicine, and Pathology.
[96] E. Leung,et al. Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia , 2014, Pacing and clinical electrophysiology : PACE.
[97] W. Roberts,et al. Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. , 2014, The American journal of cardiology.
[98] Z. Demirozu,et al. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device. , 2014, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[99] Tiina Heliö,et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.
[100] V. Kamperidis,et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. , 2013, Circulation journal : official journal of the Japanese Circulation Society.
[101] N. Smedira,et al. Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract Obstruction , 2013, Circulation.
[102] Tevfik F Ismail,et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.
[103] J. Kautzner,et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. , 2013, Journal of the American College of Cardiology.
[104] B. Funke,et al. Dilated cardiomyopathy , 2007, Archives of Disease in Childhood.
[105] R. Hauer,et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.
[106] O. Ogah,et al. Cardiomyopathies and myocardial disorders in Africa: present status and the way forward , 2012, Cardiovascular journal of Africa.
[107] O. Alfieri,et al. Long-term results of mitral repair for functional mitral regurgitation in idiopathic dilated cardiomyopathy. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[108] M. Yacoub,et al. Patterns of Disease Progression in Hypertrophic Cardiomyopathy: An Individualized Approach to Clinical Staging , 2012, Circulation. Heart failure.
[109] B. Firwana,et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. , 2012, The Cochrane database of systematic reviews.
[110] J. McMurray,et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta‐analysis † , 2012, European journal of heart failure.
[111] C. Phornphutkul,et al. The emerging phenotype of long-term survivors with infantile Pompe disease , 2012, Genetics in Medicine.
[112] J. Butterfield,et al. Treatment of hypereosinophilic syndromes--the first 100 years. , 2012, Seminars in hematology.
[113] C. Kramer,et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. , 2012, JACC. Cardiovascular imaging.
[114] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] John Mitchell,et al. Cardiac Angiogenic Imbalance Leads to Peri-partum Cardiomyopathy , 2012, Nature.
[116] L. Mestroni,et al. Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.
[117] C. O'connor,et al. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. , 2012, American heart journal.
[118] B. Bornstein,et al. Genetic basis of end‐stage hypertrophic cardiomyopathy , 2011, European journal of heart failure.
[119] D. Hughes,et al. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease. , 2011, Molecular genetics and metabolism.
[120] L. Cooper,et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. , 2011, Journal of the American College of Cardiology.
[121] J. Tharakan. Electrocardiogram in Endomyocardial Fibrosis , 2011, Indian pacing and electrophysiology journal.
[122] M. Enriquez-Sarano,et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.
[123] P. Elliott,et al. Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. , 2011, Journal of the American College of Cardiology.
[124] L. Køber,et al. Heart failure etiology impacts survival of patients with heart failure. , 2011, International journal of cardiology.
[125] V. Figueredo. Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. , 2011, The American journal of medicine.
[126] M. Kupari,et al. Cardiac Sarcoidosis and Giant Cell Myocarditis as Causes of Atrioventricular Block in Young and Middle-Aged Adults , 2011, Circulation. Arrhythmia and electrophysiology.
[127] S. Kushwaha,et al. Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2011, Circulation. Heart failure.
[128] Saibal Kar,et al. Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.
[129] Marco Merlo,et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. , 2011, Journal of the American College of Cardiology.
[130] Paul J. Wang,et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) , 2011, Circulation.
[131] G. Brittenham,et al. Iron-chelating therapy for transfusional iron overload. , 2011, The New England journal of medicine.
[132] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[133] J. Gorman,et al. Percutaneous repair or surgery for mitral regurgitation. , 2011, The New England journal of medicine.
[134] G. Oudit,et al. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. , 2010, Journal of cardiac failure.
[135] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[136] R. Porcher,et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. , 2010, European journal of medical genetics.
[137] K. Sliwa,et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.
[138] W. Manning,et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.
[139] A. Angelini,et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy , 2010, European heart journal.
[140] S. Solomon,et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. , 2010, European heart journal.
[141] Michael J Ackerman,et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.
[142] D. Mele,et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment , 2010, Cardiovascular ultrasound.
[143] M. Sheppard,et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .
[144] G. Boriani,et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.
[145] R. Schiffmann,et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data , 2009, The Lancet.
[146] M. Yacoub,et al. The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice , 2009, Journal of cardiovascular translational research.
[147] C. Poggesi,et al. Mechanical and Energetic Consequences of HCM-Causing Mutations , 2009, Journal of cardiovascular translational research.
[148] Carolyn Y. Ho. Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype , 2009, Journal of cardiovascular translational research.
[149] Barry J Maron,et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.
[150] Andrea Frustaci,et al. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.
[151] E. Braunwald,et al. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.
[152] J. Seidman,et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. , 2009, JAMA.
[153] J. Seidman,et al. Clinical Outcome and Phenotypic Expression in LAMP 2 Cardiomyopathy , 2009 .
[154] D. Annane,et al. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics , 2009, Heart Failure Reviews.
[155] K. Bailey,et al. Usefulness of immunosuppression for giant cell myocarditis. , 2008, The American journal of cardiology.
[156] W. Manning,et al. Response to Letter Regarding Article, “Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy” , 2009 .
[157] K. Sliwa,et al. Reversal of IFN‐γ, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy , 2008, European journal of heart failure.
[158] M. Yacoub,et al. A population study of endomyocardial fibrosis in a rural area of Mozambique. , 2008, The New England journal of medicine.
[159] Rachael,et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. , 2008, Mayo Clinic proceedings.
[160] P. Lambiase,et al. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end‐stage hypertrophic cardiomyopathy , 2008, European journal of heart failure.
[161] Eloisa Arbustini,et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.
[162] C. Stellbrink,et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.
[163] M. Beer,et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. , 2007, European heart journal.
[164] D. Fassbender,et al. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response , 2007, Clinical Research in Cardiology.
[165] D. Nansera,et al. Echocardiographic, chest X-ray and electrocardiogram findings in children presenting with heart failure to a Ugandan paediatric ward , 2007, Tropical doctor.
[166] P. Elliott,et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. , 2007, Journal of the American College of Cardiology.
[167] D. Tsiapras,et al. NT‐proBNP levels and diastolic dysfunction in β‐Thalassaemia major patients , 2007 .
[168] J. Zamorano,et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. , 2007, European heart journal.
[169] M. Yacoub,et al. 'End-stage' hypertrophic cardiomyopathy: from mystery to model , 2007, Nature Clinical Practice Cardiovascular Medicine.
[170] A. Hamdy. Use of strain and tissue velocity imaging for early detection of regional myocardial dysfunction in patients with beta thalassemia. , 2007, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[171] K. Sliwa,et al. A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy , 2007, Cell.
[172] R. Finkel,et al. Agalsidase-Beta Therapy for Advanced Fabry Disease , 2007, Annals of Internal Medicine.
[173] P. Elliott,et al. Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives , 2006, Circulation.
[174] D. Tsiapras,et al. NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients. , 2007, European journal of heart failure.
[175] Stanley D. Kosanke,et al. Mimicry and Antibody-Mediated Cell Signaling in Autoimmune Myocarditis1 , 2006, The Journal of Immunology.
[176] M. Link,et al. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.
[177] B. Maron,et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). , 2006, The American journal of cardiology.
[178] W. Manning,et al. Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.
[179] T. Kubo,et al. Long-Term Prognosis of Dilated Cardiomyopathy Revisited , 2006 .
[180] V. Valero,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[181] J. Tardiff. Sarcomeric Proteins and Familial Hypertrophic Cardiomyopathy: Linking Mutations in Structural Proteins to Complex Cardiovascular Phenotypes , 2005, Heart failure reviews.
[182] A. Tajik,et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[183] K. Sliwa,et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. , 2005, American heart journal.
[184] W. Mckenna,et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.
[185] B. Maron,et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[186] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[187] P. Elliott,et al. The natural history of left ventricular systolic function in Anderson-Fabry disease , 2005, Heart.
[188] H. Bécane,et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. , 2005, Journal of the American College of Cardiology.
[189] Katherine C. Wu,et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. , 2005, The New England journal of medicine.
[190] K. Adams,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.
[191] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[192] J. Atherton,et al. Biventricular diastolic behaviour in patients with hypertrophic and hereditary hemochromatosis cardiomyopathies. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[193] Hugh Calkins,et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.
[194] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[195] M. Skinner,et al. Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.
[196] A. Mehta,et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey , 2004, European journal of clinical investigation.
[197] N. Olivieri,et al. Iron overload cardiomyopathies: New insights into an old disease , 1994, Cardiovascular Drugs and Therapy.
[198] R. Hui,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.
[199] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[200] A. Matsumori,et al. Gene expression of cardiac mast cell chymase and tryptase in a murine model of heart failure caused by viral myocarditis. , 2003, Circulation journal : official journal of the Japanese Circulation Society.
[201] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[202] A. Tajik,et al. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.
[203] Sheryl E. Koch,et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy , 2003, Nature Medicine.
[204] D. Corrado,et al. Screening for hypertrophic cardiomyopathy in a young male military population. , 2003, The American journal of cardiology.
[205] G. Thiene,et al. Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.
[206] B. Maron,et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.
[207] A. Matsumori,et al. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey , 2002, Heart.
[208] D N Firmin,et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.
[209] B. Maron,et al. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.
[210] M C Oz,et al. Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.
[211] D. Kremastinos. Heart Failure in β‐Thalassemia , 2001 .
[212] M. Isobe,et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.
[213] D. Tsiapras,et al. Heart failure in beta thalassemia: a 5-year follow-up study. , 2001, The American journal of medicine.
[214] M. Cowie,et al. The epidemiological features of heart failure in developing countries: a review of the literature. , 2001, International journal of cardiology.
[215] D. Kremastinos. Heart failure in beta-thalassemia. , 2001, Congestive heart failure.
[216] J. Cohn,et al. Baseline demographics of the Valsartan Heart Failure Trial , 2000, European journal of heart failure.
[217] J. Towbin,et al. Sudden Death and Cardiovascular Collapse in Children With Restrictive Cardiomyopathy , 2000 .
[218] J B Seward,et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. , 2000, Circulation.
[219] M Pohl,et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. , 2000, Journal of the American College of Cardiology.
[220] L. Fauchier,et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. , 2000, European heart journal.
[221] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[222] M. Condorelli,et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. , 1999, The American journal of cardiology.
[223] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[224] D. Corrado,et al. Screening for hypertrophic cardiomyopathy in young athletes. , 1998, The New England journal of medicine.
[225] O. Schober,et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. , 1998, Circulation research.
[226] M. Rich,et al. CONGESTIVE HEART FAILURE IN OLDER ADULTS * : Epidemiology, Pathophysiology, and Etiology of Congestive Heart Failure in Older Adults , 1997, Journal of the American Geriatrics Society.
[227] E. J. Brown,et al. The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.
[228] B Maisch,et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.
[229] R. Falk,et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. , 1996, The American journal of medicine.
[230] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[231] M A Rossi,et al. The challenge of chagasic cardiomyopathy. The pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications. , 1995, Cardiology.
[232] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.
[233] L. Wilkins. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.
[234] L. Mestroni,et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy , 1994, The Lancet.
[235] P. Rickenbacher,et al. Incidence of myocarditis in peripartum cardiomyopathy. , 1994, The American journal of cardiology.
[236] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[237] P. Steinherz,et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.
[238] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[239] H. Schultheiss,et al. Antibodies to ADP-ATP carrier--an autoantigen in myocarditis and dilated cardiomyopathy--impair cardiac function. , 1990, Circulation.
[240] L. Melton,et al. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. , 1989, Circulation.
[241] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[242] T. Sakamoto,et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. , 1987 .
[243] A. Falase,et al. Degranulated eosinophils, eosinophil granule basic proteins and humoral factors in Nigerians with endomyocardial fibrosis. , 1987, African journal of medicine and medical sciences.
[244] W. Robinson,et al. Reversible cardiac dysfunction in hemochromatosis. , 1987, American heart journal.
[245] J. Chauvet,et al. Results, indications and contra-indications of surgery in restrictive endomyocardial fibrosis: comparative study on 31 operated and 30 non-operated patients. , 1985, East African medical journal.
[246] W. Roberts,et al. Cardiovascular disease in the very elderly , 1983 .
[247] W. Roberts,et al. Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over. , 1983, The American journal of cardiology.
[248] V. Fuster,et al. The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.
[249] G. Hutchins,et al. Cardiac Sarcoid: A Clinicopathologic Study of 84 Unselected Patients with Systemic Sarcoidosis , 1978, Circulation.
[250] A. Torp. Incidence of congestive cardiomyopathy. , 1978, Postgraduate medical journal.
[251] A. K. Patel,et al. Survival after first presentation with endomyocardial fibrosis. , 1972, British heart journal.